The National Products Association Challenges FDA’s Interpretation of the Dietary Supplement Exclusionary Clause
FDA Law Blog: Biosimilars
SEPTEMBER 18, 2024
Under FDA’s interpretation, it is impossible to determine whether there is a non-public IND prior to starting work on developing an ingredient as a dietary supplement. However, FDA’s interpretation creates that exact risk for a dietary supplement manufacturer who invests in development of a dietary supplement.
Let's personalize your content